The information on this page is intended for healthcare professionals. Some of the products and services shown here may not be available in your country or region.
Oct. 12, 2021

Clinical Insights: MASTER DAPT Study 2021 Results Unveiled

The clinical data from this investigator-initiated MASTER DAPT (MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen) study demonstrates that one month of DAPT was non-inferior to treatment continuation for at least 2 additional months for the occurrence of net and major adverse clinical events, and reduced major or clinically relevant non-major bleeding.

To find out more about the study, visit the page below.

*MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and a data management group (CERC, Paris, France; Cardialysis, Rotterdam, The Netherlands; CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).